首页> 美国卫生研究院文献>Vaccines >Increased Immunogenicity of Full-Length Protein Antigens through Sortase-Mediated Coupling on the PapMV Vaccine Platform
【2h】

Increased Immunogenicity of Full-Length Protein Antigens through Sortase-Mediated Coupling on the PapMV Vaccine Platform

机译:通过PapMV疫苗平台上的分选酶介导的偶联增加了全长蛋白抗原的免疫原性。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Flexuous rod-shape nanoparticles—made of the coat protein of papaya mosaic virus (PapMV)—provide a promising vaccine platform for the presentation of viral antigens to immune cells. The PapMV nanoparticles can be combined with viral antigens or covalently linked to them. The coupling to PapMV was shown to improve the immune response triggered against peptide antigens (<39 amino acids) but it remains to be tested if large proteins can be coupled to this platform and if the coupling will lead to an immune response improvement. Methods: Two full-length recombinant viral proteins, the influenza nucleoprotein (NP) and the simian immunodeficiency virus group-specific protein antigen (GAG) were coupled to PapMV nanoparticles using sortase A. Mice were immunized with the nanoparticles coupled to the antigens and the immune response directed to the antigens were analyzed by ELISA and ELISPOT. Results: We showed the feasibility of coupling two different full-length proteins (GAG and NP) to the nanoparticle. We also showed that the coupling to PapMV nanoparticles improved significantly the humoral and the cytotoxic T lymphocyte (CTL) immune response to the antigens. Conclusion: This proof of concept demonstrates the versatility and the efficacy of the PapMV vaccine platform in the design of vaccines against viral diseases.
机译:背景:由木瓜花叶病毒(PapMV)的外壳蛋白制成的棒状纳米颗粒为将病毒抗原呈递给免疫细胞提供了一个有前途的疫苗平台。 PapMV纳米颗粒可以与病毒抗原结合或与它们共价连接。已显示与PapMV的偶联可改善针对肽抗原(<39个氨基酸)触发的免疫应答,但是否可以将大蛋白偶联至该平台以及偶联是否会导致免疫应答改善尚待测试。方法:使用分选酶A将两种全长重组病毒蛋白,流感病毒核蛋白(NP)和猿猴免疫缺陷病毒群特异性蛋白抗原(GAG)偶联到PapMV纳米颗粒上。通过ELISA和ELISPOT分析针对抗原的免疫应答。结果:我们显示了将两种不同的全长蛋白质(GAG和NP)偶联到纳米颗粒上的可行性。我们还表明,与PapMV纳米颗粒的偶联显着改善了对抗原的体液和细胞毒性T淋巴细胞(CTL)免疫反应。结论:这一概念证明证明了PapMV疫苗平台在设计针对病毒性疾病的疫苗中的多功能性和有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号